2-benzylmercapto-3-phenylpropionic acid | 31644-91-4

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 苯丙酸
• 英文名称: 2-benzylmercapto-3-phenylpropionic acid
• 英文别名: 2-(benzylthio)-3-phenylpropanoic acid；α-Benzylthiohydrozimtsaeure；2-Benzylsulfanyl-3-phenylpropanoic acid
• CAS: 31644-91-4
• 化学式: C₁₆H₁₆O₂S
• 分子量: 272.368
• InChiKey: PLMUIHBYYKZNAF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  19
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  62.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  S-苄基巯基乙酸 在 sodium hydroxide 、 sodium tetrahydroborate 、 sodium benzylsulfanylacetate 作用下， 以 乙酸酐 为溶剂， 生成 2-benzylmercapto-3-phenylpropionic acid
  参考文献：
  名称：

  联苯苄基乙二醛和水杨基乙二醛的生产

  摘要：

  用苄硫基乙酸和苯甲醛或α-巯基肉桂酸和苄基氯以多种方式制备α-苯甲硫基肉桂酸（熔点115-123°）。结果表明，大的mp间隔取决于多态性。通过从热苯中重结晶，得到熔点为123°的酸。将α-苄基硫代肉桂酸添加物还原为α-苄基硫代肉桂酸（熔点65°）。由苄硫基乙酸和水杨醛制备3-苄硫基香豆素（mp 168°）。

  DOI：

  10.1016/s0040-4020(01)92483-4

文献信息

• CARBOXYLIC DERIVATIVES FOR USE IN THE TREATMENT OF CANCER
  申请人：Aymami Bofarull Juan

  公开号：US20110105544A1

  公开（公告）日：2011-05-05

  The invention provides novel compounds of formula (I), wherein: R 1 is a radical derived from one of the known ring systems; R 2 is a phenyl radical optionally substituted; X n represents a birradical selected from the group consisting of: —(CH 2 ) 1-4 —, (C 2 -C 4 )-alkenyl, (C 2 -C 4 )alkynyl, —S—(CH 2 ) 1-3 —#, and —(CH 2 ) 1-3 —O—#; wherein the symbol # indicates the position at which X n is attached to R 1 ; Y n is a birradical selected from the group consisting of: —(CH 2 ) 2-4 —, —S—(CH 2 ) 1-3 #, and —O—(CH 2 ) 1-3 —#; wherein the symbol # indicates the position at which Y n is attached to R 2 ; and R 3 is a radical selected from the group consisting of: —OR 4 . The compounds of formula (I) are useful in the treatment of cancer.

  本发明提供了式（I）的新化合物，其中：R1是从已知环系中派生的基团；R2是可选取代的苯基基团；Xn代表从以下群组中选择的双基团：—（CH2）1-4—，（C2-C4）-烯基，（C2-C4）炔基，—S—（CH2）1-3—#，和—（CH2）1-3—O—#；其中符号#表示Xn连接到R1的位置；Yn代表从以下群组中选择的双基团：—（CH2）2-4—，—S—（CH2）1-3#，和—O—（CH2）1-3—#；其中符号#表示Yn连接到R2的位置；R3是从以下群组中选择的基团：—OR4。式（I）的化合物在癌症治疗中有用。
• Renin inhibitors III
  申请人：WARNER-LAMBERT COMPANY

  公开号：EP0271862A2

  公开（公告）日：1988-06-22

  The invention concerns novel renin-inhibitory peptides of the formula which are useful for the manufacture of pharmaceuticals for treating renin associated hypertension, hyperaldosteronism, and congestive heart failure. Processes for preparing the peptides and compositions containing them are included. Also described is a diagnostic test using the compounds to determine the presence of renin-associated hypertension or hyperaldosteronism.

  本发明涉及式中的新型肾素抑制肽，可用于制造治疗肾素相关性高血压、高醛固酮症和充血性心力衰竭的药物。 本发明还包括制备肽的工艺和含有肽的组合物。 本发明还描述了一种诊断测试，使用这些化合物来确定是否存在肾素相关性高血压或高醛固酮症。
• Searching for Minimum Increments of Hydrophobic Collapse: Flexible Dinaphthyl Carboxylates
  作者：Lisa F. Newcomb、Tasir S. Haque、Samuel H. Gellman

  DOI：10.1021/ja00129a014

  日期：1995.6

  In an effort to identify minimal units of hydrophobically induced folding, we have examined flexible molecules containing two naphthyl moieties connected by a four-atom linker that also bears a carboxyl group. Crystallographic data show that the linkers allow intramolecular edge-to-face association of the naphthyl groups without excessive strain in the backbone. For the carboxylate forms of the dinaphthyl compounds, the occurrence of intramolecular naphthyl-naphthyl proximity in aqueous solution (24 degrees C) was detected via upfield shifts in the aromatic region H-1 NMR signals, relative to mononaphthyl control compounds. The naphthyl-naphthyl proximity does not appear to be strongly ''hydrophobically driven'', however, because similar upfield shifts (dinaphthyl vs mononaphthyl carboxylates) were observed in 8 M aqueous urea, and for the corresponding carboxylic acids in CDCl3 and C6D6. We conclude that these upfield shifts largely reflect chance encounters between the naphthyl groups resulting from random conformational motion.
• US4895834A
  申请人：——

  公开号：US4895834A

  公开（公告）日：1990-01-23
• [EN] CARBOXYLIC DERIVATIVES FOR USE IN THE TREATMENT OF CANCER<br/>[FR] DÉRIVÉS CARBOXYLIQUES DESTINÉS À ÊTRE UTILISÉS DANS LE TRAITEMENT DU CANCER
  申请人：CRYSTAX PHARMACEUTICALS S L

  公开号：WO2009080722A2

  公开（公告）日：2009-07-02

  The invention provides novel compounds of formula (I), wherein: R1 is a radical derived from one of the known ring systems; R2 is a phenyl radical optionally substituted; Xn represents a birradical selected from the group consisting of: -(CH2)1-4-, (C2-C4)-alkenyl, (C2-C4)alkynyl, -S-(CH2)1-3-#, and - (CH2)1-3-O-#; wherein the symbol # indicates the position at which Xn is attached to R1; Yn is a birradical selected from the group consisting of: - (CH2)2-4-, -S-(CH2)1-3#, and -O-(CH2)1-3-#,; wherein the symbol # indicates the position at which Yn is attached to R2; and R3 is a radical selected from the group consisting of: -OR4. The compounds of formula (I) are useful in the treatment of cancer.